Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 9, 2007, Pages 1045-1052

  Sinha, Sunil K ^a   Bhangoo, Amrit ^a   Anhalt, Henry ^b   Maclaren, Noel ^c   Marshall, Jan D ^d   Collin, Gayle B ^d   Naggert, Jürgen K ^d   Ten, Svetlana ^a,e  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d JACKSON LABORATORY   (United States)

^e NONE   (United States)

Author keywords

Adrenarche; ALMSI; Alstr m syndrome; Insulin resistance; Metformin; Obesity; Rosiglitazone

Indexed keywords

INSULIN; METFORMIN; ROSIGLITAZONE;

ABSENCE OF SIDE EFFECTS; ACANTHOSIS NIGRICANS; ALSTROM SYNDROME; ARTICLE; BLINDNESS; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFECT; EXON; HETEROZYGOSITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONSENSE MUTATION; NYSTAGMUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHOTOSENSITIVITY; PREPUBERTY; SCHOOL CHILD; WEIGHT GAIN;

EID: 35648940831     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.9.1045     Document Type: Article

References (27)

1. Alström CH, Hallgren B, Nilsson LB, Åsander H. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness. A specific syndrome (not hitherto described) distinct from Laurence-Moon-Biedl syndrome. A clinical endocrinological and genetic examination based on a large pedigree. Acta Psychiatr Neurol Scand 1959; 34 (Suppl 129): 1-35.
2. Charles SJ, Moore AT, Yates JR, Green T, Clark P. Alström's syndrome: further evidence of autosomal recessive inheritance and endocrinological dysfunction. Am J Med Genet 1990; 27: 590-592.
3. Michaud JI, Heon E., Guilbert F, Weill J, Puech B, Benson L, Smallhorn JF, Shuman CT, Buncic JR, Levin AV Weksberg R, Breviere GM. Natural history of Alström syndrome in early childhood: onset with dilated cardiomyopathy. J Pediatr 1996; 128: 225-229.
4. Connolly MB, Jan JE, Couch RM, Wong LT, Dimmick JE, Rigg JM. Hepatic dysfunction in Alström disease. Am J Med Genet 1991; 40: 421-424.
5. Marshall JD, Ludman MD, Shea SE, Salisbury SR, Willi SM, LaRoche RG, Nishina PM. Genealogy, natural history, and phenotype of Alström syndrome in a large Acadian kindred and three additional families. Am J Med Genet 1997; 73: 150-161.
6. Warren, SE, Schnitt SJ, Bauman AJ, Gianelly RE, Landsberg L, Baim DS. Late onset dilated cardiomyopathy in a unique familial syndrome of hypogonadism and metabolic abnormalities. Am Heart J 1987; 114: 1522-1524.
7. Alter CA, Moshang T Jr. Growth hormone deficiency in two siblings with Alström syndrome. Am J Dis Child 1993; 147: 97-99.
8. Collin GB, Marshall JD, Cardon LP, Nishina PM. Homozygosity mapping of Alström syndrome to chromosome 2p. Hum Mol Genet 1997; 6: 213-219.
9. Hearn T, Renforth GL, Spalluto C, Hanley NA, Piper Y, Brickwood S, White C, Connolly V, Taylor JF, Russell-Eggift I, Bonneau D, Walker M, Wilson DI. Mutation of ALA61, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome. Nat Genet 2002; 31: 79-83.
10. Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, Beck S, Boerkoel CF, Sicolo N, Martin M, Nishina, PM, Naggert JK. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome. Nat Genet 2002; 31: 74-78.
11. Marshall JD, Bronson RT, Collin GB, Nordstrom AD, Maffei P, Paisey RB, Carey C, Macdermott S, Russell-Eggitt I, Shea SE, Davis J, Beck S, Shatirishvili G, Mihai CM, Hoeltzenbein M, Pozzan GB, Hopkinson I, Sicolo N, Naggert JK, Nishina. PM. New Alström syndrome phenotypes based on the evaluation of 182 cases. Arch Int Med 2005; 165: 675-683.
12. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
13. Leboviti HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patient with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
14. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
15. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the miminal model method and the euglycemic glucose clamp. J Clin Invest 1987; 79: 790-800.
16. Weyer C, Tataranni P, Bogardus C, Pratley R. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000; 24: 89-94.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
18. Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167-175.
19. Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ, Breg WR, Jones HW Jr, Rary JM. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 1997; 74: 1245-1249
20. Satman I, Yilmaz MT, Gursoy N, Karsidag K, Dinccag N, Ovali T, Karadeniz S, Uysal V, Bugra Z, Okten A, Devrim S. Evaluation of insulin resistant diabetes mellitus in Alström syndrome: a long-term prospective follow-up of three siblings. Diabetes Res Clin Pract 2002; 56: 189-196.
21. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-623.
22. Rique S, Ibanez L, Marcos MV, Carrascosa A, Potau N. Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome. Diabetologia 2000; 43: 385-386.
23. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003; 25 (Suppl B): B32-46.
24. The DREAM Trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fisting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.
25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120: 1183-1192.
26. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
27. Wang CH, Leung CH, Liu SC, Chung CH. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease. J Formos Med Assoc 2006; 105: 743-752.